Subscribe to our Newsletters !!
Infections pose an everpresent threat to society a
Biotech Fluidics has introduced a durable dual sta
A new COVID-19 variant, BA.3.2, informally called
The sustained tensions between Iran and the United
For a number of years now, healthcare systems glob
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
Drug firm Alembic Pharmaceuticals on Monday said it has received establishment inspection report (EIR) from the US health regulator for its new injectable facility at Karakhadi in Gujarat.
The company has, ”received EIR from US Food and Drug Administration (USFDA) for the inspection carried out by them at our new injectable facility at Karakhadi during the period from January 28, 2021 to February 6, 2021, indicating that the USFDA finds our responses to their observations to be adequate,” Alembic Pharmaceuticals said in a regulatory filing.
The US regulator has also indicated that a compliance verification would be performed during re-inspection of the said facility in the next review cycle, it added.
Shares of Alembic Pharmaceuticals closed at Rs 819.45 per scrip on BSE, up 5.42 per cent from its previous close.
